Pharmaceutical

Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07264660?

PF-07264660 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).

Jul 2, 2024 - 04:00
PF-07264660 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Spur Therapeut...

Next Article

Risk adjusted net present value: What is the current valuation of CRISPR Therape...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Defender’s plans for motion sickness nasal gel stop with FDA rejection

Defender’s plans for motion sickness nasal gel stop wit...

Jan 31, 2024

UK MHRA approves ViiV Healthcare’s cabotegravir formulations for HIV-1

UK MHRA approves ViiV Healthcare’s cabotegravir formula...

May 7, 2024

Three lessons from Covid that could help global leaders prevent the next pandemic

Three lessons from Covid that could help global leaders...

Sep 6, 2023